H.E. Gall

1.1k total citations
31 papers, 892 citations indexed

About

H.E. Gall is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, H.E. Gall has authored 31 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 4 papers in Surgery. Recurrent topics in H.E. Gall's work include Chemotherapy-induced organ toxicity mitigation (10 papers), Metal complexes synthesis and properties (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). H.E. Gall is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (10 papers), Metal complexes synthesis and properties (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). H.E. Gall collaborates with scholars based in Netherlands, Germany and Belgium. H.E. Gall's co-authors include Herbert M. Pinedo, I. Klein, E. Boven, Jan B. Vermorken, W. J. F. van der Vijgh, A. Leyva, W J van der Vijgh, Paul A. Maessen, K. Mross and C.J. van Groeningen and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

H.E. Gall

31 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.E. Gall Netherlands 15 420 304 155 93 88 31 892
Ezra M. Greenspan United States 17 258 0.6× 230 0.8× 91 0.6× 121 1.3× 81 0.9× 62 951
Alberts Ds United States 19 486 1.2× 517 1.7× 86 0.6× 130 1.4× 90 1.0× 53 1.3k
Carl G. Schmidt Germany 13 265 0.6× 349 1.1× 86 0.6× 84 0.9× 58 0.7× 33 798
N. I. Nissen Denmark 19 373 0.9× 252 0.8× 196 1.3× 157 1.7× 80 0.9× 58 1.0k
M. Lehnert Switzerland 19 702 1.7× 361 1.2× 176 1.1× 154 1.7× 130 1.5× 40 1.1k
P. Dodion Belgium 20 446 1.1× 484 1.6× 120 0.8× 204 2.2× 46 0.5× 72 1.1k
Karen Oliva Australia 18 320 0.8× 451 1.5× 67 0.4× 140 1.5× 97 1.1× 34 1.1k
Takao Ohnuma United States 22 462 1.1× 592 1.9× 121 0.8× 174 1.9× 93 1.1× 81 1.5k
Pooja Advani United States 17 358 0.9× 219 0.7× 100 0.6× 107 1.2× 40 0.5× 67 799
James Gilmour Morrison United Kingdom 17 257 0.6× 179 0.6× 119 0.8× 55 0.6× 30 0.3× 34 926

Countries citing papers authored by H.E. Gall

Since Specialization
Citations

This map shows the geographic impact of H.E. Gall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.E. Gall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.E. Gall more than expected).

Fields of papers citing papers by H.E. Gall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.E. Gall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.E. Gall. The network helps show where H.E. Gall may publish in the future.

Co-authorship network of co-authors of H.E. Gall

This figure shows the co-authorship network connecting the top 25 collaborators of H.E. Gall. A scholar is included among the top collaborators of H.E. Gall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.E. Gall. H.E. Gall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ávalos, Gerardo, et al.. (2025). Plant size influences specific leaf area in palms: a case for the diminishing returns hypothesis. Oecologia. 207(4). 56–56. 1 indexed citations
2.
Bonnet, Udo, et al.. (2015). Zur Differenzialdiagnose des quälenden psychogenen chronischen Hustens: neuropathischer Larynx irritable – Gabapentin als Antitussivum. Fortschritte der Neurologie · Psychiatrie. 83(10). 568–577. 2 indexed citations
3.
Peters, Godefridus J., Paul Noordhuis, André B. P. Kuilenburg, et al.. (2003). Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 52(1). 1–12. 39 indexed citations
4.
Baars, Arnold, A.M.E. Claessen, John Wagstaff, et al.. (2002). A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. British Journal of Cancer. 86(8). 1230–1234. 21 indexed citations
5.
Baars, Arnold, A.M.E. Claessen, H.E. Gall, et al.. (2000). Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients. Annals of Oncology. 11(8). 965–970. 49 indexed citations
6.
Eertwegh, Alfons J.M. van den, A.M.E. Claessen, Harm van Tinteren, et al.. (2000). Actieve specifieke immunotherapie als adjuvante behandeling van patiënten met coloncarcinoom in stadium II of III: prospectief gerandomiseerd onderzoek. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 144(6). 274–279. 1 indexed citations
7.
Gall, H.E., et al.. (1994). Anticonvulsiva-Hypersensitivit�ts-Syndrom auf Carbamazepin. Der Hautarzt. 45(7). 494–498. 7 indexed citations
8.
Arrigo, C., et al.. (1994). The involvement of nurses in clinical trials; Results of the EORTC Oncology Nurses Study Group survey. Cancer Nursing. 17(5). 429???433–429???433. 21 indexed citations
9.
10.
Groeningen, C.J. van, H.E. Gall, A. C. Van Loenen, et al.. (1989). Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.. PubMed. 35(5-6). 283–94. 1 indexed citations
11.
Schwartsmann, Gilberto, W. J. F. van der Vijgh, I. Klein, et al.. (1989). Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study. European Journal of Cancer and Clinical Oncology. 25(12). 1675–1681. 16 indexed citations
12.
Gall, H.E., et al.. (1988). Late Results after Sclerotherapy of Varicocele. European Urology. 14(2). 115–119. 6 indexed citations
13.
Vijgh, W. J. F. van der, F. Elferink, Jan B. Vermorken, et al.. (1988). Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua(1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial. European Journal of Cancer and Clinical Oncology. 24(4). 621–627. 2 indexed citations
14.
Mross, K., Paul A. Maessen, W J van der Vijgh, et al.. (1988). Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.. Journal of Clinical Oncology. 6(3). 517–526. 156 indexed citations
15.
Elferink, F., JB Vermorken, I. Klein, et al.. (1987). Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial. British Journal of Cancer. 56(4). 479–483. 3 indexed citations
16.
Gall, H.E.. (1987). [Diagnosis of varicocele with bidirectional Doppler sonography. A contribution to the pathogenesis of varicocele].. PubMed. 38(5). 271–8. 3 indexed citations
17.
Elferink, F., W J van der Vijgh, I. Klein, et al.. (1987). Pharmacokinetics of carboplatin after i.v. administration.. PubMed. 71(12). 1231–7. 60 indexed citations
18.
Winograd, Benjamin, J. B. Vermorken, W.W. ten Bokkel Huinink, et al.. (1986). Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.. PubMed. 46(4 Pt 2). 2148–51. 6 indexed citations
19.
Vermorken, J. B., W. J. F. van der Vijgh, I. Klein, H.E. Gall, & Herbert M. Pinedo. (1982). Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. PubMed. 18(11). 1069–1074. 62 indexed citations
20.
Schmid, Michael, H.E. Gall, W. Schempp, Lee Weber, & Jörg Schmidtke. (1981). Characterization of a new aberration of the human Y chromosome by banding methods and DNA restriction endonuclease analysis. Human Genetics. 59(1). 26–35. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ezra M. Greenspan Breakdown of academic impact, for papers by Alberts Ds Breakdown of academic impact, for papers by Carl G. Schmidt Breakdown of academic impact, for papers by N. I. Nissen Breakdown of academic impact, for papers by M. Lehnert Breakdown of academic impact, for papers by P. Dodion Breakdown of academic impact, for papers by Karen Oliva Breakdown of academic impact, for papers by Takao Ohnuma Breakdown of academic impact, for papers by Pooja Advani Breakdown of academic impact, for papers by James Gilmour Morrison
Rankless by CCL
2026